Merck Receives Japanese Approval for Subcutaneous Version of Keytruda
Merck (MRK) has received regulatory approval from Japan for the subcutaneous version of its cancer immunotherapy drug, KEYTRUDA QLEX. This new formulation includes pembrolizumab and berahyaluronidase alfa-pmph and is approved across all indications currently authorized in Japan. The subcutaneous injection can be administered within one minute every three weeks, offering a more convenient delivery method compared to intravenous administration. The approval marks an important step for Merck's oncology portfolio expansion in the Japanese market.
Tickers: $MRK
Topics: drug approval KEYTRUDA pharmaceuticals